Ironwood Pharmaceuticals is a global leader in gastrointestinal (GI) healthcare, dedicated to advancing the treatment of GI diseases and redefining care standards for patients. The company is known for its pioneering work in developing LINZESS (linaclotide), which is the leading prescription treatment in the U.S. for adults suffering from irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood is also focused on creating innovative therapies for rare GI conditions, with a notable product candidate, apraglutide, currently in Phase 3 development for short bowel syndrome. By prioritizing patient needs in its research and commercialization efforts, Ironwood aims to reduce the burden of GI diseases and address significant unmet medical needs, making it a compelling workplace for those passionate about making a real impact in healthcare.